ChemoCentryx (CCXI) Tops Q3 EPS by 13c

ChemoCentryx (NASDAQ: CCXI) reported Q3 EPS of ($0.32), $0.13 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $17.7 million versus the consensus estimate of $13.48 million.

For earnings history and earnings-related data on ChemoCentryx (CCXI) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Is Treasury selloff a major issue for stock market bulls?